Shanghai Pharmaceuticals (China) Performance
| 601607 Stock | 21.30 0.45 2.07% |
On a scale of 0 to 100, Shanghai Pharmaceuticals holds a performance score of 9. The entity has a beta of 0.4, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Shanghai Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Shanghai Pharmaceuticals is expected to be smaller as well. Please check Shanghai Pharmaceuticals' downside deviation, information ratio, and the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether Shanghai Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Shanghai Pharmaceuticals Holding are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Shanghai Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Payout Ratio 0.4537 | Last Split Factor 1.2:1 | Ex Dividend Date 2024-09-24 | Last Split Date 2007-08-16 |
1 | Shanghai Pharmaceuticals Declares Interim Dividend - TipRanks | 09/02/2024 |
| Begin Period Cash Flow | 24.5 B |
Shanghai |
Shanghai Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,892 in Shanghai Pharmaceuticals Holding on September 3, 2024 and sell it today you would earn a total of 283.00 from holding Shanghai Pharmaceuticals Holding or generate 14.96% return on investment over 90 days. Shanghai Pharmaceuticals Holding is generating 0.2622% of daily returns and assumes 2.1014% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than Shanghai, and 95% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Shanghai Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Shanghai Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Shanghai Pharmaceuticals Holding, and traders can use it to determine the average amount a Shanghai Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1248
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 601607 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.1 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Shanghai Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Shanghai Pharmaceuticals by adding it to a well-diversified portfolio.
Shanghai Pharmaceuticals Fundamentals Growth
Shanghai Stock prices reflect investors' perceptions of the future prospects and financial health of Shanghai Pharmaceuticals, and Shanghai Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Shanghai Stock performance.
| Return On Equity | 0.0641 | ||||
| Return On Asset | 0.0241 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 79.38 B | ||||
| Shares Outstanding | 2.79 B | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 0.26 X | ||||
| Revenue | 260.3 B | ||||
| Gross Profit | 28.41 B | ||||
| EBITDA | 9.62 B | ||||
| Net Income | 3.77 B | ||||
| Total Debt | 35.56 B | ||||
| Book Value Per Share | 19.13 X | ||||
| Cash Flow From Operations | 5.23 B | ||||
| Earnings Per Share | 1.08 X | ||||
| Total Asset | 211.97 B | ||||
| Retained Earnings | 33.82 B | ||||
About Shanghai Pharmaceuticals Performance
By analyzing Shanghai Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Shanghai Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Shanghai Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Shanghai Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Shanghai Pharmaceuticals is entity of China. It is traded as Stock on SHG exchange.Things to note about Shanghai Pharmaceuticals performance evaluation
Checking the ongoing alerts about Shanghai Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Shanghai Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Shanghai Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| About 66.0% of the company shares are owned by insiders or employees |
- Analyzing Shanghai Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Shanghai Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Shanghai Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Shanghai Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Shanghai Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Shanghai Pharmaceuticals' stock. These opinions can provide insight into Shanghai Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Shanghai Stock analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |